BPMC241220C130000
- 0.50
- +0.32+177.78%
Blueprint Medicines Newsroom
Express News | Guggenheim Reiterates Buy on Blueprint Medicinesto Buy
Blueprint Medicines Analyst Ratings
Barclays Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $105
Express News | Reported Saturday, Blueprint Medicines Showcases AYVAKIT'S Survival Benefits And Disease-Modifying Effects In Advanced Systemic Mastocytosis At ASH 2024
Blueprint Medicines: A Promising Investment With Innovative Treatments and Strong Financial Position
Insider Sale: CHIEF OPERATING OFFICER of $BPMC (BPMC) Sells 2,274 Shares
Big Pharma Pushes To Revise Biden-era Medicare Drug Price Negotiation Law Under Trump
Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue?
Vertex Leads J.P. Morgan's Top Biotech Picks List for 2025
Breakeven On The Horizon For Blueprint Medicines Corporation (NASDAQ:BPMC)
Blueprint Medicines Insider Sold Shares Worth $1,869,658, According to a Recent SEC Filing
Express News | Blueprint Medicines Corp : Raymond James Raises Target Price to $130 From $125
JMP Securities Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $125
TD Cowen Maintains Blueprint Medicines(BPMC.US) With Buy Rating
H.C. Wainwright Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $135
Morgan Stanley Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $120
Needham Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $135
Express News | Needham Reiterates Buy on Blueprint Medicines, Maintains $135 Price Target
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst
J.P. Morgan Initiates Blueprint Medicines(BPMC.US) With Buy Rating, Announces Target Price $126